
SignifyMD makes expert medical insights accessible and actionable for today’s oncologists and HCPs. #Oncology #Cancer #MedTwitter
Joined June 2024
- Tweets549
- Following688
- Followers179
- Likes1.4K
SignifyMD retweeted
Early detection matters! 💗
I'm sharing my personal breast cancer story and how a routine screening mammogram led to an early diagnosis that made all the difference.
Watch my story and learn why early detection is so important. Get screened—it could save your life! 🎀
Breast cancer doctor faces her own diagnosis goodmorningamerica.com/video… via @GMA
SignifyMD retweeted
⭐️ Toxicity, Bridging & Shared Decision-Making in CAR T for #MultipleMyeloma
🎙️ @OncBrothers w/ @Bethfaiman , @Rfonsi1 & Carrie Bellerive, RN
👉 Broad 2L eligibility + bridging to ↓ burden/neurotox risk
👉 Early education, caregiver involvement & cross-center coordination
👉 Close CRS/ICANS monitoring + IVIG consideration
#mmsm #CART #OncTwitter #MedEd
🎥 Full discussion +summary👇
oncupdates.com/video-podcast…
SignifyMD retweeted
Replying to @OncUpdates @OncBrothers @sdent_cardioonc @hoperugo @ErikaHamilton9 @PTarantinoMD @hmcarthur @DrSAHaddad @JasmineKambojMD @HundalJasmin @drsarahsam @royaryam @SPremji7866 @RoswellPark @WilmotCancer @SignifyMD
Worth attending for the TNBC session alone. Immunotherapy combinations in that space are still evolving fast, and hearing how the panel weighs new SABCS data would be valuable. #bcsm
SignifyMD retweeted
⭐️ #ESMO26 | #HERIZON-GEA-01: OS benefit with zanidatamab regimens in 1L HER2+ mGEA
🎙️ @KlempnerSam & @ShrutiPatelMD
✅ mOS: 22.9 vs 19.6 mo (HR 0.76) zani+chemo vs tras+chemo
✅ Triplet mOS: 27 mo
#GIOnc #HER2 #OncTwitter #gism
🎥 Full discussion 👇
oncupdates.com/video-podcast…
SignifyMD retweeted
⭐️ Ep. 1: Tissue vs Liquid Biopsy Testing in HR+ mBC
🎙️ @OncBrothers + @VKaklamani @KalinskyKevin @DrWGradishar & Dr. Nazarullah discuss when and how to use tissue vs ctDNA in HR+/HER2− metastatic breast cancer.
#bcsm #BreastCancer #OncTwitter
🎥 👇
oncupdates.com/video-podcast…
SignifyMD retweeted
🤩 #HemOnc Fellows, are you going to #ASH26? Join for a FREE board review!
👀 Here is a sneak peek of your board review day!
🗓️ In-person w/@OncBrothers + @TwoOncDocs
🔗 Register: bit.ly/hemeboards
#OncTwitter #MedX #MedTwitter #ASH @HemOncFellows @hemeoncfellow
SignifyMD retweeted
There is an especially outlandish conspiracy theory that oncologists are hiding the cure for cancer
Its proponents must think us particularly noble, then, when we sacrifice our lives to keep the secret: forgoing a panacea and succumbing to the very disease we treat
Dr. Shroff is not the only “wounded healer” I’ve known, but her legacy is far more than the wretched illness that claimed her own life too soon
She did her very best to push oncology forward, especially for patients with notoriously difficult-to-treat biliary tract cancers (a close relative, anatomically and sometimes pathophysiologically, to pancreatic adenocarcinoma)
I remember her incredible humility to stand at the podium at one of our largest scientific conferences and admit that a triplet therapy had not produced the benefits she had hoped for, allowing biological plausibility to cede to data yielded from the clinical trial she conceived & ran
Our field is full of such examples of good ideas failing to reach fruition, but we can only get better by admitting what’s not working as well as promoting true advances
When the history books are written, most, if not all chemo will look like grand folly, akin to our modern view of, say, blood-letting
But it is because of visionary physician-scientists like Rachna that we are making any progress at all: doing the best we can today while realizing there must be a better way and testing rigorously our ideas of how we might get there
May she be remembered in part for her tireless work, born out of irrepressible hope and true caring for her own patients as well as ones she never met (she never failed to kindly & helpfully answer a question I posed to her when I faced a management conundrum in her niche of cholangiocarcinoma)
RIP to a dear colleague (link in post below to a fund for young investigators named & bestowed in her honor)
We join the oncology community in mourning the passing of Dr. Rachna T. Shroff, a renowned GI cancers expert and a dedicated ASCO volunteer. We are humbled by her dedication and strive to honor her legacy of commitment and altruism.
Read more: bit.ly/4e7jBKu
SignifyMD retweeted
Next few months are going to be busy! #SABCS26 -> #ASH26 -> #GI27 ->#GU27
During #GI27 we will get a chance to touch on the data in person. We would love to see you there!
In Person Jan 22, 2027 w/ @YJanjigianMD @DrShubhamPant @NVijayvergiaMD @MDmanishshah @smitha42
Register bit.ly/aiogi27
#OncTwitter #gism
SignifyMD retweeted
Comprehensive review article by Sara Hurvitz @fredhutch on state of the art advances in MBC treatment, published in @NEJM. This is also a timely reference for MDs and scientists and to cite in papers, grants, presentations. @SusanGKomen @BCRFcure @ASCO @AACR @PIK3CApathbreak
nejm.org/doi/full/10.1056/NE…
SignifyMD retweeted
Excited to report that FDA has approved atezolizumab + FP and oxali as adjuvant therapy for stage 3 dMMR colon cancer. Important advance for patients worldwide. @FASinicropeMD @MayoCancerCare @MayoClinic @ASCO @AACR @ASCOPost @myESMO @ALLIANCE_org
FDA approves new treatment option, #atezolizumab in combination with chemotherapy, for patients with stage III dMMR #coloncancer based on results from the phase III #ATOMIC trial led by @ALLIANCE_org. Learn more: bit.ly/FDA-ATOMIC @theNCI #NCTN #CancerResearch #CRCsm
SignifyMD retweeted
Atezolizumab is now @FDA ✅ off #ATOMIC Ph III, adj mFOLFOX + Atezo vs. mFOLFOX in Stg III dMMR colon ca.
- 3yr DFS 86.4% vs 76.6% (HR 0.50)
- OS not mature
- ⬆️ Gr4 neutropenia with Atezo.
- How much is chemo benefitting? Role of NICHE2?
- @ASCO Plenary!
#gism #OncTwitter
SignifyMD retweeted
⭐️ #EXCALIBER-RRMM: Iberdomide + Dara + Dex in RRMM
✅ mPFS 42 vs 20 mo with DVd
👉 Confirmatory PFS for the MRD-based approval
⚠️ Neutropenia, infections, VTE
#mmsm #MultipleMyeloma #OncTwitter #HemOnc #OncUpdates #MedTwitter #MedX
🔗Full Summary 👇
oncupdates.com/article/iberd…
SignifyMD retweeted
In Small Cell Lung Cancer “Challenging Case” discussion with @Latinamd & @drshieldsmd:
✅ Limited & Extensive Stg
✅ MAVERICK data
✅ Supportive care
✅ Maintenance & Sequencing
Full 🗣️:
⭐️ oncbrothers.com/cc-sclc-2026
⭐️ “Oncology Brothers” podcast
#OncTwitter @OncoAlert
SignifyMD retweeted
From appreciating broader treatment landscape to acknowledging regional differences, #EOS2026 @SocietyEmirates was a great learning experience. Our personal highlights!
#OncTwitter
SignifyMD retweeted
Today’s approval makes 11 in #breastcancer since May 1! Google “FDA oncology approvals” for searchable list of heme/oncology FDA approvals (2006 to now) w/ a concise description of each, in reverse chronological order. A+ for Boards prep or clinical practice. #OncTwitter #bcsm
Pretty stunning review on advances in breast cancer treatment in this week’s NEJM
So many new approvals since 2020 that they could only fit on a 2-page centerfold!!!
Looks like it’s the roaring 20s in breast cancer research!
#bcsm
SignifyMD retweeted
🤔Going to #SABCS26?
📍Join Us for the @OncBrothers #AIO event!
🗓️In Person Dec 9th,2026
⭐️Faculty Panel @sdent_cardioonc @hoperugo @ErikaHamilton9 @PTarantinoMD @hmcarthur + DrSaraHurvitz
🔗Register: bit.ly/aiosabcs26
#bcsm #OncTwitter #BreastCancer @SABCSSanAntonio
SignifyMD retweeted
And then in September 2026: we got 5 more new drugs/indications ✅ @FDADrugs!! As a #CommunityOncologists, we need to know them all:
1. #Camizestrant in mESR1 HR+ breast cancer (before progression). ⬆️mPFS (16mos vs. 9.2mos)
2. #Imlunestrant + #Abemaciclib in 2L metastatic mESR1 HR+ breast cancer. ⬆️mPFS (11.1mos vs. 5.5mos)
3. #Sevabertinib now in 1L Her2 mutated NSCLC. ORR 75%
4. #Lirafugratinib in 2L for FGFR2 fusion/rearrangement cholangiocarcinoma. ORR 46% and DoR 11.8mos
5. #Belzutifan + #Lenvatinib in 2L RCC. ⬆️mPFS (14.6mos vs. 10.6mos)
#OncTwitter #bcsm #lcsm #gusm @OncUpdates @FDA @US_FDA
What just happened in Oncology? 5 new drugs/indications ✅ @FDADrugs in August 2026. As a #CommunityOncologists, we need to know them all:
1. #Rusfertide in Polycythemia Vera, improved phlebotomy (76.9% vs. 32.9%)
2. #Daraxonrasib in 2L metastatic pancreatic cancer, mOS 13.2 Vs 6.7mos
3. #Zanidatamab + Chemo ± Tislelizumab in 1L metastatic Her2+ GEA/Gastric adenocarcinoma, mOS 26.4mos Vs 19.2mos
4. #Iberdomide + Dara + Dex in 2L RRMM, improved MRD negativity (41% vs. 21%)
5. #Vusolimogene + Nivo in refractory Melanoma. ORR of 24.2% and mDOR: 14.1mos.
#pancsm #mpnsm #OncTwitter #HemeTwitter @OncoAlert @OncUpdates
SignifyMD retweeted
Are you going to be at #SABCS26? Let’s talk through current SoC & how #SABCS26 will change this!
InPerson: Dec 9, 2026 w/ @sdent_cardioonc @hoperugo @ErikaHamilton9 @PTarantinoMD @hmcarthur & DrSaraHurvitz
Register: bit.ly/aiosabcs26
#AdvInOnc26 #OncTwitter @OncoAlert
SignifyMD retweeted
🤩 Join us at #ASH26 w/@OncBrothers
🗓️ in-person event on December 13th
🤩 Featured Guest Experts: @DrBrandyeMD @mshadman @lymphomaphilia @SoniSmithMD @DrHKantarjian @RaajitRampal @VincentRK @DrKrinaPatel
Register👇
oncologybrothers.regfox.com/…
#AdvInOnc26 #OncTwitter #ASH #MedX



























